Wednesday, September 24, 2025 NEC3 (Alliance A021202) was a randomized phase II trial of pazopanib versus placebo in patients with advanced extrapancreatic neuroendocrine tumorsBergsland EK, Geyer S, Asmis TR, Behr SC, Kuebler JP, Kumthekar P, Mazza G, Maitland ML, Niedzwiecki D, Nixon AB, Schwartz LH, Strosberg Jr, Venook AP, O'Reilly EM, Meyerhardt JA. Randomized Phase II Trial of Pazopanib Versus Placebo in Patients With Advanced Extrapancreatic Neuroendocrine Tumors (Alliance A021202) (ONLINE). Journal of Clinical Oncology 2025.https://ascopubs.org/doi/abs/10.1200/JCO-24-02644 AboutDoes the vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor (TKI) pazopanib have activity in extrapancreatic neuroendocrine tumors (epNETs)? The results suggest pazopanib has activity in epNETs and contribute to the growing evidence that VEGF is a valid target for therapy in this disease. However, the efficacy benefit of pazopanib needs to be weighed against the increased toxicity, more on-study deaths, and worse patient-reported symptoms compared with placebo.
